Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24660854 | 0.91 | PKM (0.38) | PKMANPEPCA12CA2CA3 | |
| SCHEMBL6696856 | 0.86 | — | — | |
| SCHEMBL6696847 | 0.86 | — | — | |
| SCHEMBL8109376 | 0.85 | PKM (0.41) | PKMCA12CA2CA9 | |
| SCHEMBL3015969 | 0.84 | CA12 (0.48) | PKMANPEPCA12CA2CA3 | |
| SCHEMBL3013403 | 0.83 | — | — | |
| SCHEMBL28834532 | 0.82 | CA12 (0.50) | PKMANPEPCA12CA2CA3 | |
| SCHEMBL3424464 | 0.81 | LMNA (0.38) | PKMCA12CA2CA9LMNA | |
| SCHEMBL24459735 | 0.80 | CA12 (0.48) | PKMCA12CA2CA3CA4 | |
| SCHEMBL27656089 | 0.79 | TDP1 (0.53) | PKMANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110996897-A | Skin external composition containing ceramide, its derivative and cortex Hibisci extract | 株式会社爱茉莉太平洋 | 2020-04-10 | — | — | CN | disclosed |
| US-8337649-B2 | Repair film and use thereof | BASF COATINGS GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| EP-2422780-A1 | Resistance-repellent retroviral protease inhibitors | Sequoia Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2422781-A1 | Resistance-repellent retroviral protease inhibitors | Sequoia Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20100056596-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056596-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100009935-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009935-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS (US) | 2010-01-14 | — | — | US | disclosed |
| US-7507763-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507763-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090011189-A1 | REFINISH SHEETS AND THEIR USE | BASF COATINGS AG (DE) | 2009-01-08 | — | — | US | disclosed |
| US-7378441-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378441-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7285566-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. | 2007-10-23 | — | — | US | disclosed |
| US-7285566-B2 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS, INC. | 2007-10-23 | — | — | US | disclosed |
| WO-2005110428-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2000006151-A9 | SUSTAINED RELEASE NITRIC OXIDE PRODUCING AGENTS | KUHRTS ERIC (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009935-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SERPINB1, MMP7, MME | PKM 3882/4885ANPEP 45/4885CA12 4388/4885 |
| US-20100056596-A1 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SERPINB1, MMP7, MME | PKM 3882/4885ANPEP 45/4885CA12 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.